Alacrita Aggregates the Life Science Practices of Two Consulting Firms
News May 10, 2013
Alacrita has aggregated the life science practices of two consulting firms and appointed Simon Turner PhD FRSC as Partner.
Alacrita is taking on the business of Canopus, a specialist life science consulting firm founded by Dr. Turner, which recently acquired the life sciences consulting business of Transentia, which focussed on the commercialization of early-stage technology.
The move consolidates Alacrita’s position as a leading life science consulting firm and expands the firm’s partnership to more effectively serve its growing roster of transatlantic clients.
Simon has over two decades of experience managing and advising on strategic and product development issues in the life science industry.
Over the past ten years, Simon has focused on commercialization of life science technologies as entrepreneur, executive, venture capital investor and advisor.
In 2000, Simon became Chief Executive of Biotica Technology, a venture-capital backed drug-discovery company, which he led for five years. He has since been involved as investor and advisor to biotechnology companies in two investment firms and more recently through Canopus.
He gained extensive strategic management consulting experience in life sciences whilst working at Arthur D Little and Andersen Consulting.
Financial details of the transaction were not disclosed.
Simon Turner said “I am delighted to be joining Alacrita at an exciting stage in its evolution. There are tremendous synergies between our two businesses, in particular, Alacrita’s focus on expertise-based consulting through its network of senior consultants with deep expertise and many years of industry experience. Alacrita has consistently demonstrated its ability to deliver real value to sophisticated life science companies and investors who have needed to supplement their internal capability. I look forward to serving the firm’s expanding base of clients and building the business into a top tier consulting firm.”
Rob Johnson, Partner at Alacrita, said: “We are delighted to welcome Simon to the Alacrita partnership. He is a very experienced management consultant and his strategic insight is rooted in reality, having first-hand experience of leading a biotech company as CEO of Biotica. He has deep and broad technological knowledge of the life science industry and a sound understanding of the challenges faced by senior management. His appointment represents an exciting development for our business and underlines our commitment to providing exceptionally high quality advice to the industry.”
Anthony Walker, Partner at Alacrita, added: “Alacrita’s consulting practice has been growing on both sides of the Atlantic, and Simon joining the partnership reinforces our capacity to grow further. On a personal note, I have known and worked with Simon at various times over many years, and it is a real pleasure to welcome him to Alacrita.”
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018